Systemic sclerosis (SSc) is a multisystem fibrotic disorder characterized by autoimmunity, vasculopathy, and progressive fibrosis affecting multiple organs. Unlike other fibrotic diseases, autoimmunity and vasculopathy precede fibrosis in SSc. Despite extensive research, no therapy has been able to reverse or significantly slow fibrosis. Recent studies have identified cellular and molecular mechanisms underlying fibrosis, including the role of TGF-β, CTGF, and other factors. Animal models, such as the Tsk1 mouse and bleomycin-induced models, have been used to study SSc pathogenesis. The disease involves microvascular injury, inflammation, and autoimmunity leading to fibrosis. Fibrosis is driven by fibroblast activation, myofibroblast transdifferentiation, and ECM remodeling. Key factors include TGF-β, CTGF, and cytokines like IL-4 and IL-13. SSc fibroblasts exhibit autonomous activation, constitutive secretion of cytokines, and increased ECM synthesis. Current therapies are primarily immunomodulatory and have limited efficacy in reversing fibrosis. Future research aims to identify novel therapeutic targets, including TGF-β, CTGF, and other mediators, as well as explore the role of epigenetic regulation and signaling pathways in fibrosis. Potential therapies include drugs that block key mediators or inhibit intracellular signaling molecules. New treatments may also emerge from existing drugs used for other conditions. Understanding the complex interplay between vascular damage, autoimmunity, and fibrosis is crucial for developing effective therapies for SSc.Systemic sclerosis (SSc) is a multisystem fibrotic disorder characterized by autoimmunity, vasculopathy, and progressive fibrosis affecting multiple organs. Unlike other fibrotic diseases, autoimmunity and vasculopathy precede fibrosis in SSc. Despite extensive research, no therapy has been able to reverse or significantly slow fibrosis. Recent studies have identified cellular and molecular mechanisms underlying fibrosis, including the role of TGF-β, CTGF, and other factors. Animal models, such as the Tsk1 mouse and bleomycin-induced models, have been used to study SSc pathogenesis. The disease involves microvascular injury, inflammation, and autoimmunity leading to fibrosis. Fibrosis is driven by fibroblast activation, myofibroblast transdifferentiation, and ECM remodeling. Key factors include TGF-β, CTGF, and cytokines like IL-4 and IL-13. SSc fibroblasts exhibit autonomous activation, constitutive secretion of cytokines, and increased ECM synthesis. Current therapies are primarily immunomodulatory and have limited efficacy in reversing fibrosis. Future research aims to identify novel therapeutic targets, including TGF-β, CTGF, and other mediators, as well as explore the role of epigenetic regulation and signaling pathways in fibrosis. Potential therapies include drugs that block key mediators or inhibit intracellular signaling molecules. New treatments may also emerge from existing drugs used for other conditions. Understanding the complex interplay between vascular damage, autoimmunity, and fibrosis is crucial for developing effective therapies for SSc.